Memorial Sloan Kettering neurologist Alexandra Miller

Alexandra Miller, MD, PhD

Neuro-Oncologist & Neurologist

Clinical Expertise

Primary Brain Tumors Including Glioblastoma; Anaplastic Glioma; Low-grade Glioma; Ependymoma; Meningioma; and Central Nervous System Lymphoma; Brain Metastases (Including Leptomeningeal Disease); Neurologic Complications of Cancer

New Patient Appointments

Scheduling a visit is easy. Click below or call us to get started.

Accepted Insurance Providers

Dr. Miller accepts the following list of insurance providers. Select your insurance provider to see more details.

Contact and Location

Locations map

Find a Convenient Location

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.

About Me


MD, PhD, Yale University School of Medicine


Neurology – NewYork-Presbyterian/Weill Cornell Medical Center


Neuro-Oncology – Memorial Sloan Kettering Cancer Center

Board Certifications

Neurology; Neuro-Oncology

Awards and Honors

  • American Society of Clinical Oncology Young Investigator Award (2017)


Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

Clinical Trials

Smiling doctors in the lab

Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Research and Publications

Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N, Zheng Y, Skakodub A, Mehta SA, Campos C, Hsieh WY, Selcuklu SD, Ling L, Meng F, Jing X, Samoila A, Bale TA, Tsui DWY, Grommes C, Viale A, Souweidane MM, Tabar V, Brennan CW, Reiner AS, Rosenblum M, Panageas KS, DeAngelis LM, Young RJ, Berger MF, Mellinghoff IK. Nature. 2019 Jan 23; 565(7741):654-658. 

Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism.Sood A, Miller AM, Brogi E, Sui Y, Armenia J, McDonough E, Santamaria-Pang A, Carlin S, Stamper A, Campos C, Pang Z, Li Q, Port E, Graeber TG, Schultz N, Ginty F, Larson SM, Mellinghoff IK. JCI Insight. 2016 May 5;1(6). pii: e87030.

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, Chan TA, Graeber TG, Yen KE, Mellinghoff IK. Science. 2013 May 3;340(6132):626-30. doi: 10.1126/science.1236062. Epub 2013 Apr 4.

Prognostic awareness, prognostic communication, and cognitive function in patients with malignant glioma. Diamond EL, Prigerson HG, Correa DC, Reiner A, Panageas K, Kryza-Lacombe M, Buthorn J, Neil EC, Miller AM, DeAngelis LM, Applebaum AJ. Neuro Oncol. 2017 Oct 19;19(11):1532-1541. doi: 10.1093/neuonc/nox117.